Taiwan: These 32 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025
DrugPatentWatch® Estimated Loss of Exclusivity Dates in Taiwan
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
Friedman, Yali, "Taiwan: These 32 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025" DrugPatentWatch.com thinkBiotech, 2024 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can VIZIMPRO (dacomitinib) generic drug versions launch?
Generic name: dacomitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: Taiwan Patent 200,540,163
Patent Title: 4-Phenylamino-quinazolin-6-yl-amides
VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.
This drug has ninety-three patent family members in forty-eight countries.
See drug price trends for VIZIMPRO.
The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.
When can VIZIMPRO (dacomitinib) generic drug versions launch?
Generic name: dacomitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: Taiwan Patent I334865
VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.
This drug has ninety-three patent family members in forty-eight countries.
See drug price trends for VIZIMPRO.
The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.
When can ARCAPTA NEOHALER (indacaterol maleate) generic drug versions launch?
Generic name: indacaterol maleate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Taiwan Patent 200,613,021
Patent Title: Organic compounds
ARCAPTA NEOHALER is a drug marketed by Novartis. There are two patents protecting this drug.
This drug has eighty-six patent family members in thirty-nine countries.
See drug price trends for ARCAPTA NEOHALER.
The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.
When can ARCAPTA NEOHALER (indacaterol maleate) generic drug versions launch?
Generic name: indacaterol maleate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Taiwan Patent I353857
ARCAPTA NEOHALER is a drug marketed by Novartis. There are two patents protecting this drug.
This drug has eighty-six patent family members in thirty-nine countries.
See drug price trends for ARCAPTA NEOHALER.
The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.
When can UTIBRON (glycopyrrolate ; indacaterol maleate) generic drug versions launch?
Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Taiwan Patent 200,613,021
Patent Title: Organic compounds
UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.
This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON
See drug price trends for UTIBRON.
The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.
When can UTIBRON (glycopyrrolate ; indacaterol maleate) generic drug versions launch?
Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Taiwan Patent I353857
UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.
This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON
See drug price trends for UTIBRON.
The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.
When can VITEKTA (elvitegravir) generic drug versions launch?
Generic name: elvitegravir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 20, 2024
Generic Entry Controlled by: Taiwan Patent 200,600,097
Patent Title: Stable crystal of 4-oxoquinoline compound technical field of the invention
VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug.
This drug has ninety-two patent family members in thirty-six countries. There has been litigation on patents covering VITEKTA
The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.
When can VITEKTA (elvitegravir) generic drug versions launch?
Generic name: elvitegravir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 20, 2024
Generic Entry Controlled by: Taiwan Patent I329015
VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug.
This drug has ninety-two patent family members in thirty-six countries. There has been litigation on patents covering VITEKTA
The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.
When can CAPRELSA (vandetanib) generic drug versions launch?
Generic name: vandetanib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: Taiwan Patent 200,612,953
Patent Title: Pharmaceutical compositions
CAPRELSA is a drug marketed by Genzyme Corp. There is one patent protecting this drug.
This drug has forty patent family members in thirty-three countries.
See drug price trends for CAPRELSA.
The generic ingredient in CAPRELSA is vandetanib. One supplier is listed for this generic product. Additional details are available on the vandetanib profile page.
When can CAPRELSA (vandetanib) generic drug versions launch?
Generic name: vandetanib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: Taiwan Patent I355269
CAPRELSA is a drug marketed by Genzyme Corp. There is one patent protecting this drug.
This drug has forty patent family members in thirty-three countries.
See drug price trends for CAPRELSA.
The generic ingredient in CAPRELSA is vandetanib. One supplier is listed for this generic product. Additional details are available on the vandetanib profile page.
When can CHILDREN'S ADVIL ALLERGY SINUS (chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride) generic drug versions launch?
Generic name: chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 25, 2024
Generic Entry Controlled by: Taiwan Patent 200,600,118
Patent Title: Pharmaceutical suspension composition
CHILDREN'S ADVIL ALLERGY SINUS is a drug marketed by Haleon Us Holdings. There is one patent protecting this drug.
This drug has nine patent family members in eight countries.
The generic ingredient in CHILDREN'S ADVIL ALLERGY SINUS is chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride. There are twenty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride profile page.
When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?
Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Taiwan Patent 200,609,002
Patent Title: Coated tablet formulation and method
KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering KOMBIGLYZE XR
See drug price trends for KOMBIGLYZE XR.
The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.
When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?
Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Taiwan Patent 201,204,414
Patent Title: Coated tablet formulation and method
KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering KOMBIGLYZE XR
See drug price trends for KOMBIGLYZE XR.
The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.
When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?
Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Taiwan Patent I354569
KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering KOMBIGLYZE XR
See drug price trends for KOMBIGLYZE XR.
The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.
When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?
Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Taiwan Patent I415635
KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering KOMBIGLYZE XR
See drug price trends for KOMBIGLYZE XR.
The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.
When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?
Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Taiwan Patent 200,609,002
Patent Title: Coated tablet formulation and method
ONGLYZA is a drug marketed by Astrazeneca Ab. There is one patent protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering ONGLYZA
See drug price trends for ONGLYZA.
The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.
When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?
Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Taiwan Patent 201,204,414
Patent Title: Coated tablet formulation and method
ONGLYZA is a drug marketed by Astrazeneca Ab. There is one patent protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering ONGLYZA
See drug price trends for ONGLYZA.
The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.
When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?
Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Taiwan Patent I354569
ONGLYZA is a drug marketed by Astrazeneca Ab. There is one patent protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering ONGLYZA
See drug price trends for ONGLYZA.
The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.
When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?
Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Taiwan Patent I415635
ONGLYZA is a drug marketed by Astrazeneca Ab. There is one patent protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering ONGLYZA
See drug price trends for ONGLYZA.
The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.
When can FYCOMPA (perampanel) generic drug versions launch?
Generic name: perampanel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 06, 2024
Generic Entry Controlled by: Taiwan Patent 200,606,144
Patent Title: Crystal of 1,2-dihydropyridine compound
FYCOMPA is a drug marketed by Catalyst Pharms. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.
This drug has one hundred and one patent family members in thirty-three countries. There has been litigation on patents covering FYCOMPA
See drug price trends for FYCOMPA.
The generic ingredient in FYCOMPA is perampanel. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the perampanel profile page.
When can FYCOMPA (perampanel) generic drug versions launch?
Generic name: perampanel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 06, 2024
Generic Entry Controlled by: Taiwan Patent I346660
FYCOMPA is a drug marketed by Catalyst Pharms. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.
This drug has one hundred and one patent family members in thirty-three countries. There has been litigation on patents covering FYCOMPA
See drug price trends for FYCOMPA.
The generic ingredient in FYCOMPA is perampanel. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the perampanel profile page.
When can SUSTOL (granisetron) generic drug versions launch?
Generic name: granisetron
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 28, 2024
Generic Entry Controlled by: Taiwan Patent 200,616,650
Patent Title: Semi-solid delivery vehicle and pharmaceutical compositions
SUSTOL is a drug marketed by Heron Theraps Inc. There are five patents protecting this drug.
This drug has eighteen patent family members in ten countries.
See drug price trends for SUSTOL.
The generic ingredient in SUSTOL is granisetron. There are twenty-six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the granisetron profile page.
When can SUSTOL (granisetron) generic drug versions launch?
Generic name: granisetron
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 28, 2024
Generic Entry Controlled by: Taiwan Patent I407966
SUSTOL is a drug marketed by Heron Theraps Inc. There are five patents protecting this drug.
This drug has eighteen patent family members in ten countries.
See drug price trends for SUSTOL.
The generic ingredient in SUSTOL is granisetron. There are twenty-six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the granisetron profile page.
When can QUARTETTE (ethinyl estradiol; levonorgestrel) generic drug versions launch?
Generic name: ethinyl estradiol; levonorgestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 07, 2024
Generic Entry Controlled by: Taiwan Patent 200,626,161
Patent Title: Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
QUARTETTE is a drug marketed by Teva Branded Pharm. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has twenty-three patent family members in thirteen countries. There has been litigation on patents covering QUARTETTE
See drug price trends for QUARTETTE.
The generic ingredient in QUARTETTE is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
When can QUARTETTE (ethinyl estradiol; levonorgestrel) generic drug versions launch?
Generic name: ethinyl estradiol; levonorgestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 07, 2024
Generic Entry Controlled by: Taiwan Patent 200,831,107
Patent Title: Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
QUARTETTE is a drug marketed by Teva Branded Pharm. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has twenty-three patent family members in thirteen countries. There has been litigation on patents covering QUARTETTE
See drug price trends for QUARTETTE.
The generic ingredient in QUARTETTE is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
When can INCIVEK (telaprevir) generic drug versions launch?
Generic name: telaprevir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 29, 2024
Generic Entry Controlled by: Taiwan Patent 200,630,093
Patent Title: Dose forms
INCIVEK is a drug marketed by Vertex Pharms. There are two patents protecting this drug.
This drug has one hundred and twenty-four patent family members in thirty-eight countries.
The generic ingredient in INCIVEK is telaprevir. There are three drug master file entries for this API. Additional details are available on the telaprevir profile page.
When can INCIVEK (telaprevir) generic drug versions launch?
Generic name: telaprevir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 29, 2024
Generic Entry Controlled by: Taiwan Patent 201,424,733
Patent Title: Dose forms
INCIVEK is a drug marketed by Vertex Pharms. There are two patents protecting this drug.
This drug has one hundred and twenty-four patent family members in thirty-eight countries.
The generic ingredient in INCIVEK is telaprevir. There are three drug master file entries for this API. Additional details are available on the telaprevir profile page.
When can INCIVEK (telaprevir) generic drug versions launch?
Generic name: telaprevir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 29, 2024
Generic Entry Controlled by: Taiwan Patent I437990
INCIVEK is a drug marketed by Vertex Pharms. There are two patents protecting this drug.
This drug has one hundred and twenty-four patent family members in thirty-eight countries.
The generic ingredient in INCIVEK is telaprevir. There are three drug master file entries for this API. Additional details are available on the telaprevir profile page.
When can YONDELIS (trabectedin) generic drug versions launch?
Generic name: trabectedin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 29, 2024
Generic Entry Controlled by: Taiwan Patent 200,621,256
Patent Title: Formulations
YONDELIS is a drug marketed by Janssen Prods. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has forty-four patent family members in thirty-six countries. There has been litigation on patents covering YONDELIS
See drug price trends for YONDELIS.
The generic ingredient in YONDELIS is trabectedin. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the trabectedin profile page.
When can YONDELIS (trabectedin) generic drug versions launch?
Generic name: trabectedin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 29, 2024
Generic Entry Controlled by: Taiwan Patent I296523
YONDELIS is a drug marketed by Janssen Prods. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has forty-four patent family members in thirty-six countries. There has been litigation on patents covering YONDELIS
See drug price trends for YONDELIS.
The generic ingredient in YONDELIS is trabectedin. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the trabectedin profile page.
When can HORIZANT (gabapentin enacarbil) generic drug versions launch?
Generic name: gabapentin enacarbil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 04, 2024
Generic Entry Controlled by: Taiwan Patent 200,630,086
Patent Title: Gaba analog prodrug sustained release oral dosage forms
HORIZANT is a drug marketed by Azurity. There are five patents protecting this drug.
This drug has one hundred and forty-six patent family members in twenty-six countries.
See drug price trends for HORIZANT.
The generic ingredient in HORIZANT is gabapentin enacarbil. There are twenty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the gabapentin enacarbil profile page.
When can HORIZANT (gabapentin enacarbil) generic drug versions launch?
Generic name: gabapentin enacarbil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 04, 2024
Generic Entry Controlled by: Taiwan Patent I377938
HORIZANT is a drug marketed by Azurity. There are five patents protecting this drug.
This drug has one hundred and forty-six patent family members in twenty-six countries.
See drug price trends for HORIZANT.
The generic ingredient in HORIZANT is gabapentin enacarbil. There are twenty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the gabapentin enacarbil profile page.
When can KUVAN (sapropterin dihydrochloride) generic drug versions launch?
Generic name: sapropterin dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 17, 2024
Generic Entry Controlled by: Taiwan Patent 200,624,120
Patent Title: Stable tablet formulation
KUVAN is a drug marketed by Biomarin Pharm. There are ten patents protecting this drug and three Paragraph IV challenges.
This drug has one hundred and seventeen patent family members in twenty-six countries. There has been litigation on patents covering KUVAN
See drug price trends for KUVAN.
The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the sapropterin dihydrochloride profile page.
When can NEVANAC (nepafenac) generic drug versions launch?
Generic name: nepafenac
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 02, 2024
Generic Entry Controlled by: Taiwan Patent 200,626,132
Patent Title: Topical nepafenac formulations
NEVANAC is a drug marketed by Harrow Eye. There are three patents protecting this drug.
This drug has twenty-seven patent family members in twenty-three countries.
See drug price trends for NEVANAC.
The generic ingredient in NEVANAC is nepafenac. There are eight drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the nepafenac profile page.
When can NEVANAC (nepafenac) generic drug versions launch?
Generic name: nepafenac
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 02, 2024
Generic Entry Controlled by: Taiwan Patent I358290
NEVANAC is a drug marketed by Harrow Eye. There are three patents protecting this drug.
This drug has twenty-seven patent family members in twenty-three countries.
See drug price trends for NEVANAC.
The generic ingredient in NEVANAC is nepafenac. There are eight drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the nepafenac profile page.
When can DUTREBIS (lamivudine; raltegravir potassium) generic drug versions launch?
Generic name: lamivudine; raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: Taiwan Patent 200,631,944
Patent Title: Potassium salt of an HIV integrase inhibitor
DUTREBIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.
This drug has ninety-five patent family members in forty-three countries.
The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. There are twenty-nine drug master file entries for this API. Additional details are available on the lamivudine; raltegravir potassium profile page.
When can DUTREBIS (lamivudine; raltegravir potassium) generic drug versions launch?
Generic name: lamivudine; raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: Taiwan Patent I344463
DUTREBIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.
This drug has ninety-five patent family members in forty-three countries.
The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. There are twenty-nine drug master file entries for this API. Additional details are available on the lamivudine; raltegravir potassium profile page.
When can ISENTRESS (raltegravir potassium) generic drug versions launch?
Generic name: raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: Taiwan Patent 200,631,944
Patent Title: Potassium salt of an HIV integrase inhibitor
ISENTRESS is a drug marketed by Msd Sub Merck. There are six patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and twenty-five patent family members in forty-five countries.
See drug price trends for ISENTRESS.
The generic ingredient in ISENTRESS is raltegravir potassium. There are five drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the raltegravir potassium profile page.
When can ISENTRESS (raltegravir potassium) generic drug versions launch?
Generic name: raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: Taiwan Patent I344463
ISENTRESS is a drug marketed by Msd Sub Merck. There are six patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and twenty-five patent family members in forty-five countries.
See drug price trends for ISENTRESS.
The generic ingredient in ISENTRESS is raltegravir potassium. There are five drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the raltegravir potassium profile page.
When can BELRAPZO (bendamustine hydrochloride) generic drug versions launch?
Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: Taiwan Patent 200,637,614
Patent Title: Bendamustine pharmaceutical compositions
BELRAPZO is a drug marketed by Eagle Pharms. There are nine patents protecting this drug. Six tentatively approved generics are ready to enter the market.
This drug has sixty-four patent family members in thirty countries.
See drug price trends for BELRAPZO.
The generic ingredient in BELRAPZO is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.
When can BELRAPZO (bendamustine hydrochloride) generic drug versions launch?
Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: Taiwan Patent I380830
BELRAPZO is a drug marketed by Eagle Pharms. There are nine patents protecting this drug. Six tentatively approved generics are ready to enter the market.
This drug has sixty-four patent family members in thirty countries.
See drug price trends for BELRAPZO.
The generic ingredient in BELRAPZO is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.
When can BENDEKA (bendamustine hydrochloride) generic drug versions launch?
Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: Taiwan Patent 200,637,614
Patent Title: Bendamustine pharmaceutical compositions
BENDEKA is a drug marketed by Eagle Pharms. There are eighteen patents protecting this drug and one Paragraph IV challenge. Six tentatively approved generics are ready to enter the market.
This drug has one hundred and fourteen patent family members in thirty-one countries. There has been litigation on patents covering BENDEKA
See drug price trends for BENDEKA.
The generic ingredient in BENDEKA is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.
When can BENDEKA (bendamustine hydrochloride) generic drug versions launch?
Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: Taiwan Patent I380830
BENDEKA is a drug marketed by Eagle Pharms. There are eighteen patents protecting this drug and one Paragraph IV challenge. Six tentatively approved generics are ready to enter the market.
This drug has one hundred and fourteen patent family members in thirty-one countries. There has been litigation on patents covering BENDEKA
See drug price trends for BENDEKA.
The generic ingredient in BENDEKA is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.
When can WAKIX (pitolisant hydrochloride) generic drug versions launch?
Generic name: pitolisant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 10, 2025
Generic Entry Controlled by: Taiwan Patent 200,639,157
Patent Title: New salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
WAKIX is a drug marketed by Harmony. There are three patents protecting this drug.
This drug has sixty-one patent family members in thirty-one countries. There has been litigation on patents covering WAKIX
See drug price trends for WAKIX.
The generic ingredient in WAKIX is pitolisant hydrochloride. One supplier is listed for this generic product. Additional details are available on the pitolisant hydrochloride profile page.
When can WAKIX (pitolisant hydrochloride) generic drug versions launch?
Generic name: pitolisant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 10, 2025
Generic Entry Controlled by: Taiwan Patent I393711
WAKIX is a drug marketed by Harmony. There are three patents protecting this drug.
This drug has sixty-one patent family members in thirty-one countries. There has been litigation on patents covering WAKIX
See drug price trends for WAKIX.
The generic ingredient in WAKIX is pitolisant hydrochloride. One supplier is listed for this generic product. Additional details are available on the pitolisant hydrochloride profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: Taiwan Patent 200,716,635
Patent Title: Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.
This drug has one hundred and twenty-five patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: Taiwan Patent 200,800,988
Patent Title: Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.
This drug has one hundred and twenty-five patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.
When can VOCABRIA (cabotegravir sodium) generic drug versions launch?
Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: Taiwan Patent I378931
VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.
This drug has one hundred and twenty-five patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.
When can CORLANOR (ivabradine) generic drug versions launch?
Generic name: ivabradine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: Taiwan Patent 200,640,872
Patent Title: &ggr;-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR
See drug price trends for CORLANOR.
The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.
When can CORLANOR (ivabradine) generic drug versions launch?
Generic name: ivabradine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: Taiwan Patent I314143
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR
See drug price trends for CORLANOR.
The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.
When can CORLANOR (ivabradine hydrochloride) generic drug versions launch?
Generic name: ivabradine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: Taiwan Patent 200,640,873
Patent Title: &bgr-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR
See drug price trends for CORLANOR.
The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.
When can CORLANOR (ivabradine hydrochloride) generic drug versions launch?
Generic name: ivabradine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: Taiwan Patent I314144
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR
See drug price trends for CORLANOR.
The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.
When can NEXAVAR (sorafenib tosylate) generic drug versions launch?
Generic name: sorafenib tosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 07, 2025
Generic Entry Controlled by: Taiwan Patent 200,700,093
Patent Title: Pharmaceutical composition for the treatment of cancer
NEXAVAR is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has eighty-nine patent family members in thirty-nine countries. There has been litigation on patents covering NEXAVAR
See drug price trends for NEXAVAR.
The generic ingredient in NEXAVAR is sorafenib tosylate. There are thirteen drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the sorafenib tosylate profile page.
When can NEXAVAR (sorafenib tosylate) generic drug versions launch?
Generic name: sorafenib tosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 07, 2025
Generic Entry Controlled by: Taiwan Patent I324928
NEXAVAR is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has eighty-nine patent family members in thirty-nine countries. There has been litigation on patents covering NEXAVAR
See drug price trends for NEXAVAR.
The generic ingredient in NEXAVAR is sorafenib tosylate. There are thirteen drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the sorafenib tosylate profile page.
When can OZEMPIC (semaglutide) generic drug versions launch?
Generic name: semaglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 18, 2025
Generic Entry Controlled by: Taiwan Patent 200,700,433
Patent Title: Acylated glp-1 compounds
OZEMPIC is a drug marketed by Novo. There are twenty-one patents protecting this drug.
This drug has two hundred and twenty-six patent family members in twenty-eight countries. There has been litigation on patents covering OZEMPIC
See drug price trends for OZEMPIC.
The generic ingredient in OZEMPIC is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.
When can OZEMPIC (semaglutide) generic drug versions launch?
Generic name: semaglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 18, 2025
Generic Entry Controlled by: Taiwan Patent 200,942,255
Patent Title: Acylated GLP-1 compounds
OZEMPIC is a drug marketed by Novo. There are twenty-one patents protecting this drug.
This drug has two hundred and twenty-six patent family members in twenty-eight countries. There has been litigation on patents covering OZEMPIC
See drug price trends for OZEMPIC.
The generic ingredient in OZEMPIC is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.
When can OZEMPIC (semaglutide) generic drug versions launch?
Generic name: semaglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 18, 2025
Generic Entry Controlled by: Taiwan Patent I362392
OZEMPIC is a drug marketed by Novo. There are twenty-one patents protecting this drug.
This drug has two hundred and twenty-six patent family members in twenty-eight countries. There has been litigation on patents covering OZEMPIC
See drug price trends for OZEMPIC.
The generic ingredient in OZEMPIC is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.
When can OZEMPIC (semaglutide) generic drug versions launch?
Generic name: semaglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 18, 2025
Generic Entry Controlled by: Taiwan Patent I372629
OZEMPIC is a drug marketed by Novo. There are twenty-one patents protecting this drug.
This drug has two hundred and twenty-six patent family members in twenty-eight countries. There has been litigation on patents covering OZEMPIC
See drug price trends for OZEMPIC.
The generic ingredient in OZEMPIC is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.
When can WEGOVY (semaglutide) generic drug versions launch?
Generic name: semaglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 18, 2025
Generic Entry Controlled by: Taiwan Patent 200,700,433
Patent Title: Acylated glp-1 compounds
WEGOVY is a drug marketed by Novo. There are six patents protecting this drug.
This drug has one hundred and twenty-two patent family members in thirty-two countries. There has been litigation on patents covering WEGOVY
See drug price trends for WEGOVY.
The generic ingredient in WEGOVY is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.
When can WEGOVY (semaglutide) generic drug versions launch?
Generic name: semaglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 18, 2025
Generic Entry Controlled by: Taiwan Patent 200,942,255
Patent Title: Acylated GLP-1 compounds
WEGOVY is a drug marketed by Novo. There are six patents protecting this drug.
This drug has one hundred and twenty-two patent family members in thirty-two countries. There has been litigation on patents covering WEGOVY
See drug price trends for WEGOVY.
The generic ingredient in WEGOVY is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.
When can WEGOVY (semaglutide) generic drug versions launch?
Generic name: semaglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 18, 2025
Generic Entry Controlled by: Taiwan Patent I362392
WEGOVY is a drug marketed by Novo. There are six patents protecting this drug.
This drug has one hundred and twenty-two patent family members in thirty-two countries. There has been litigation on patents covering WEGOVY
See drug price trends for WEGOVY.
The generic ingredient in WEGOVY is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.
When can WEGOVY (semaglutide) generic drug versions launch?
Generic name: semaglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 18, 2025
Generic Entry Controlled by: Taiwan Patent I372629
WEGOVY is a drug marketed by Novo. There are six patents protecting this drug.
This drug has one hundred and twenty-two patent family members in thirty-two countries. There has been litigation on patents covering WEGOVY
See drug price trends for WEGOVY.
The generic ingredient in WEGOVY is semaglutide. Two suppliers are listed for this generic product. Additional details are available on the semaglutide profile page.
When can TYKERB (lapatinib ditosylate) generic drug versions launch?
Generic name: lapatinib ditosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 19, 2025
Generic Entry Controlled by: Taiwan Patent 200,716,204
Patent Title: Pharmaceutical composition
TYKERB is a drug marketed by Novartis. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has twenty-eight patent family members in twenty-six countries.
See drug price trends for TYKERB.
The generic ingredient in TYKERB is lapatinib ditosylate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the lapatinib ditosylate profile page.
When can XCOPRI (cenobamate) generic drug versions launch?
Generic name: cenobamate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 22, 2025
Generic Entry Controlled by: Taiwan Patent 200,722,085
Patent Title: Neurotherapeutic azole compounds
XCOPRI is a drug marketed by Sk Life. There are two patents protecting this drug.
This drug has twenty-six patent family members in twenty countries.
See drug price trends for XCOPRI.
The generic ingredient in XCOPRI is cenobamate. One supplier is listed for this generic product. Additional details are available on the cenobamate profile page.
When can XCOPRI (cenobamate) generic drug versions launch?
Generic name: cenobamate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 22, 2025
Generic Entry Controlled by: Taiwan Patent I398249
XCOPRI is a drug marketed by Sk Life. There are two patents protecting this drug.
This drug has twenty-six patent family members in twenty countries.
See drug price trends for XCOPRI.
The generic ingredient in XCOPRI is cenobamate. One supplier is listed for this generic product. Additional details are available on the cenobamate profile page.
When can LATUDA (lurasidone hydrochloride) generic drug versions launch?
Generic name: lurasidone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 26, 2025
Generic Entry Controlled by: Taiwan Patent 200,800,197
Patent Title: Pharmaceutical composition
LATUDA is a drug marketed by Sunovion Pharms Inc. There are nine patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has sixty-nine patent family members in twenty-four countries. There has been litigation on patents covering LATUDA
See drug price trends for LATUDA.
The generic ingredient in LATUDA is lurasidone hydrochloride. There are twenty-six drug master file entries for this API. Twenty-five suppliers are listed for this generic product. Additional details are available on the lurasidone hydrochloride profile page.
When can LATUDA (lurasidone hydrochloride) generic drug versions launch?
Generic name: lurasidone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 26, 2025
Generic Entry Controlled by: Taiwan Patent I359020
LATUDA is a drug marketed by Sunovion Pharms Inc. There are nine patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has sixty-nine patent family members in twenty-four countries. There has been litigation on patents covering LATUDA
See drug price trends for LATUDA.
The generic ingredient in LATUDA is lurasidone hydrochloride. There are twenty-six drug master file entries for this API. Twenty-five suppliers are listed for this generic product. Additional details are available on the lurasidone hydrochloride profile page.
When can VICTRELIS (boceprevir) generic drug versions launch?
Generic name: boceprevir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 02, 2025
Generic Entry Controlled by: Taiwan Patent 200,716,157
Patent Title: Pharmaceutical formulations and methods of treatment using the same
VICTRELIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.
This drug has one hundred and ten patent family members in thirty-three countries.
The generic ingredient in VICTRELIS is boceprevir. Additional details are available on the boceprevir profile page.
When can VICTRELIS (boceprevir) generic drug versions launch?
Generic name: boceprevir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 02, 2025
Generic Entry Controlled by: Taiwan Patent I428138
VICTRELIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.
This drug has one hundred and ten patent family members in thirty-three countries.
The generic ingredient in VICTRELIS is boceprevir. Additional details are available on the boceprevir profile page.
When can BOSULIF (bosutinib monohydrate) generic drug versions launch?
Generic name: bosutinib monohydrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 01, 2025
Generic Entry Controlled by: Taiwan Patent 200,740,797
Patent Title: Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same
BOSULIF is a drug marketed by Pf Prism Cv. There are five patents protecting this drug and two Paragraph IV challenges.
This drug has eighty-one patent family members in thirty countries. There has been litigation on patents covering BOSULIF
See drug price trends for BOSULIF.
The generic ingredient in BOSULIF is bosutinib monohydrate. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bosutinib monohydrate profile page.
DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.